In this regard, we have designed and developed a novel dual LSD1-HDAC6 inhibitor with strong potency on LSD1 as well as isoform selective activity on HDAC6 and tested its anti-cancer activity in multiple haematological cancers and further carried out mechanistic studies to understand the target engagement. This evidence concerns the gene HDAC6 and cancer.